Telmisartan alleviates collagen type&nbsp;III glomerulopathy: A case report with literature review

Guo,Qiaoyan; Liu,Lihua; Nie,Ping; Luo,Ping

doi:10.3892/etm.2020.9269

Telmisartan alleviates collagen type III glomerulopathy: A case report with literature review

Authors:
- Qiaoyan Guo
- Lihua Liu
- Ping Nie
- Ping Luo
View Affiliations

Affiliations: Department of Nephrology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
Published online on: October 5, 2020 https://doi.org/10.3892/etm.2020.9269
Article Number: 140
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Collagen type III is commonly detected in the renal interstitium and vasculature; however, it is absent in healthy glomeruli. Deposition of collagen type III in the glomerular mesangium and capillary basement membranes may arise in two rare diseases, namely collagen type III glomerulopathy (CG) and nail patella syndrome. CG is a rare glomerular disease with no specific treatment, although supportive measures for control of hypertension and edema may help to relieve symptoms. With progression to end‑stage renal disease, patients with CG may come to require dialysis and/or renal transplantation. The present study reported on a 59‑year‑old male who was diagnosed with CG nephrotic syndrome by immunohistochemical and electron microscopic examination of biopsy material. To the best of our knowledge, this is the first case reported in northeastern China. The angiotensin II blocker telmisartan was successfully used to alleviate renal symptoms and a literature review was performed. The present case supports the use of telmisartan as a first choice of treatment for CG.

View Figures

View References

1	Dong J, Wei H, Han M, Guan Y, Wu Y and Li H: Collagen type III glomerulopathy: A case report and review of 20 cases. Exp Ther Med. 10:1445–1449. 2015.PubMed/NCBI View Article : Google Scholar
2	Anitha A, Vankalakunti M, Siddini V, Babu K, Bonu R and Ballal S: Type III collagen disorders: A case report and review of literature. Indian J Pathol Microbiol. 59:75–77. 2016.PubMed/NCBI View Article : Google Scholar
3	Fogo AB, Lusco MA, Najafian B and Alpers CE: AJKD atlas of renal pathology: Type III collagen glomerulopathy. Am J Kidney Dis. 69:e25–e26. 2017.PubMed/NCBI View Article : Google Scholar
4	Patro KC, Jha R, Sahay M and Swarnalatha G: Collagenofibrotic glomerulopathy-case report with review of literature. Indian J Nephrol. 21:52–55. 2011.PubMed/NCBI View Article : Google Scholar
5	Rørtveit R, Eggertsdóttir AV, Thomassen R, Lingaas F and Jansen JH: A clinical study of canine collagen type III glomerulopathy. BMC Vet Res. 9(218)2013.PubMed/NCBI View Article : Google Scholar
6	Liu H, Chen J, Zhang Y, Wang S and Zou W: Clinicopathologic features of collagen III glomerulopathy. Zhonghua Bing Li Xue Za Zhi. 43:732–735. 2014.(In Chinese). PubMed/NCBI
7	Malik S, Suchal K, Gamad N, Dinda AK, Arya DS and Bhatia J: Telmisartan ameliorates cisplatin-induced nephrotoxicity by inhibiting MAPK mediated inflammation and apoptosis. Eur J Pharmacol. 748:54–60. 2015.PubMed/NCBI View Article : Google Scholar
8	Kwon YJ, Suh GH, Kang SS and Kim HJ: Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine. Can Vet J. 59:759–762. 2018.PubMed/NCBI
9	Liang W, Chen C, Shi J, Ren Z, Hu F, van Goor H, Singhal PC and Ding G: Disparate effects of eplerenone, amlodipine and telmisartan on podocyte injury in aldosterone-infused rats. Nephrol Dial Transplant. 26:789–799. 2011.PubMed/NCBI View Article : Google Scholar
10	Mikami D, Kimura H, Kamiyama K, Torii K, Kasuno K, Takahashi N, Yoshida H and Iwano M: Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells. Hypertens Res. 37:422–431. 2014.PubMed/NCBI View Article : Google Scholar
11	Wang ZK, Liu ZY and Yu HB: Protective effect of telmisartan on rats with renal failure and its mechanism. Asian Pac J Trop Med. 8:498–501. 2015.PubMed/NCBI View Article : Google Scholar
12	Kunitomi M, Wada J, Miyatake N, Hayashi Y, Ota K and Makino H: Ultrastructure of mesangial type III collagen deposition in a patient with IgA nephropathy. Am J Kidney Dis. 32:146–152. 1998.PubMed/NCBI View Article : Google Scholar
13	Ng YF, Chow CY, Yang WS, Lye WC and Loh HL: Collagenofibrotic glomerulopathy-report of a rare renal disease with serial biopsies. Malays J Pathol. 42:131–135. 2020.PubMed/NCBI
14	Matthai SM, Mohapatra A, Duhli N, David VG and Varughese S: Collagenofibrotic glomerulopathy-A rare disease diagnosed with the aid of transmission electron microscopy. Indian J Pathol Microbiol. 63:S47–S49. 2020.PubMed/NCBI View Article : Google Scholar
15	Chen X, Wang H, Xu W and Zhu J: Collagen type III glomerulopathy: Case report and review of the literature. Clin Nephrol. 87:39–46. 2017.PubMed/NCBI View Article : Google Scholar
16	Kurien AA, Larsen CP and Cossey LN: Collagenofibrotic glomerulopathy. Clin Kidney J. 8:543–547. 2015.PubMed/NCBI View Article : Google Scholar
17	Pizzo HP, Haas M and Puliyanda D: Collagen type III glomerulopathy. Kidney Int. 93(1490)2018.PubMed/NCBI View Article : Google Scholar
18	Alsaad KO, Edrees B, Rahim KA, Alanazi A, Ahmad M and Aloudah N: Collagenofibrotic (collagen type III) glomerulopathy in association with diabetic nephropathy. Saudi J Kidney Dis Transpl. 28:898–905. 2017.PubMed/NCBI
19	Cohen AH: Collagen type III glomerulopathies. Adv Chronic Kidney Dis. 19:101–106. 2012.PubMed/NCBI View Article : Google Scholar
20	Li L, Zou WZ, Wang SX, Wang SL, Wang W, Han ZH, Du J and Bo L: Collagen type III glomerulopathy: A morphologic study. Zhonghua Bing Li Xue Za Zhi. 34:385–388. 2005.(In Chinese). PubMed/NCBI
21	Bao H, Chen H, Zhu X, Xu F, Zhu M, Zhang M, He Q, Zeng C and Liu Z: Clinical and morphological features of collagen type III glomerulopathy: A report of nine cases from a single institution. Histopathology. 67:568–576. 2015.PubMed/NCBI View Article : Google Scholar
22	Vogt BA, Wyatt RJ, Burke BA, Simonton SC and Kashtan CE: Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol. 9:11–15. 1995.PubMed/NCBI View Article : Google Scholar
23	Chen N, Pan X, Xu Y, Wang Z, Shi H, Yan F and Dong X: Two brothers in one Chinese family with collagen type III glomerulopathy. Am J Kidney Dis. 50:1037–1042. 2007.PubMed/NCBI View Article : Google Scholar
24	Nimmagadda S, Mukku K, Devaraju SR and Uppin MS: Unusual cause of glomerular deposition disease: Collagenofibrotic glomerulopathy. Indian J Nephrol. 27:62–65. 2017.PubMed/NCBI View Article : Google Scholar
25	Wang K, Hu J, Luo T, Wang Y, Yang S, Qing H, Cheng Q and Li Q: Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: A systematic review and meta-analysis. Kidney Blood Press Res. 43:768–779. 2018.PubMed/NCBI View Article : Google Scholar
26	Zheng Z, Lin S and Shi H: A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension. J Clin Hypertens (Greenwich). 12:414–421. 2010.PubMed/NCBI View Article : Google Scholar
27	Bakris G, Burgess E, Weir M, Davidai G and Koval S: AMADEO Study Investigators: Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int. 74:364–369. 2008.PubMed/NCBI View Article : Google Scholar
28	Naruse M, Koike Y, Kamei N, Sakamoto R, Yambe Y and Arimitsu M: Effects of azilsartan compared with telmisartan on insulin resistance in patients with essential hypertension and type 2 diabetes mellitus: An open-label, randomized clinical trial. PLoS One. 14(e0214727)2019.PubMed/NCBI View Article : Google Scholar